PCVX · Vaxcyte, Inc.
$59.47
+0.97% last session
End-of-day data · close of 2026-09-11
Market cap
$9B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-8.2
Dividend yield
—
Beta
1.22
Avg volume
1M
Employees
1K
Daily Change %
0.97%
5 Days Change
-2.70%
10 Days Change
-2.03%
30 Days Change
0.49%
60 Days Change
2.23%
Month to Day Change
-2.14%
Year to Day Change
28.98%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PCVX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-02-26
Latest call per bank · past 12 months
Goldman Sachs
Neutral$38.00
-35.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-02-26 | BTIG | Maintains | Buy | $85.00 → $89.00 |
| 2026-02-02 | Guggenheim | Reiterates | Buy | $116 |
| 2025-11-10 | BTIG | Reiterates | Buy | $85.00 |
| 2025-10-16 | BTIG | Maintains | Buy | $160 → $85.00 |
| 2025-09-12 | Goldman Sachs | Initiates | Neutral | $0.00 → $38.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.9% above the 50-day MA ($58.38).
- Price vs 200-day MA: Trading 9.6% above the 200-day MA ($54.28).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.42) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($30.89) and high ($63.30).
PCVX Price Chart
Loading chart for PCVX…
Fundamentals
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.